Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A colorectal antigen (IOR-C2) was characterized by a monoclonal antibody produced against the colon cancer cell line SW1116. By immunohistochemical staining the antigen was abundant and strongly expressed in epithelium of normal colon whereas colorectal carcinomas showed a more variable and heterogenous reactivity to the antibody (IOR-C2). Radioimmunoprecipitates of SW1116 cell homogenates showed a 160-200 kD band in SDS gels. Physicochemical characterization indicate that at least two IOR-C2 reactive sites are present on the antigen tested and that it is mainly an 0-linked glycoprotein carbohydrate chain which can also be N-linked to the protein. The expression of IOR-C2 mimics that of the colon associated antigen (CAA) and NCC-CO-450 antigen but is distinct from these with regard to its expression in carcinomas as well as its physicochemical characteristics.
 ...
PMID:Characterization of the colorectal antigen IOR-C2. 137 20

A freeze dried kit formulation for the preparation of 99mTc-labelled IOR-CEA1, a monoclonal antibody (MoAb) against a human colorectal cancer, was developed. Methods of analysis were also established permitting identification of radiochemical impurities which may be present in radiopharmaceutical solution. 99mTc-EHDP-MoAb-IOR CEA1 prepared by the kit method was evaluated in human volunteers to apply the radioimmunodetection of human colon cancer. Data demonstrated that the complex formed after kit-reconstitution shows excellent stability and tumor seeking properties. Colon carcinoma in patients was successfully detected 6-8 and 20-28 h post administration.
 ...
PMID:A freeze dried kit formulation for the preparation of 99mTc-EHDP-MoAb-IOR CEA1 complex. 923 58